[go: up one dir, main page]

WO2004030634A3 - Compositions therapeutiques - Google Patents

Compositions therapeutiques Download PDF

Info

Publication number
WO2004030634A3
WO2004030634A3 PCT/US2003/031717 US0331717W WO2004030634A3 WO 2004030634 A3 WO2004030634 A3 WO 2004030634A3 US 0331717 W US0331717 W US 0331717W WO 2004030634 A3 WO2004030634 A3 WO 2004030634A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic compositions
therapeutic
enclosed
making
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/031717
Other languages
English (en)
Other versions
WO2004030634A2 (fr
Inventor
David Bumcrot
Nagesh Mahanthappa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Priority to AU2003282722A priority Critical patent/AU2003282722A1/en
Publication of WO2004030634A2 publication Critical patent/WO2004030634A2/fr
Publication of WO2004030634A3 publication Critical patent/WO2004030634A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des siARN et des procédés de fabrication d'utilisation de ceux-ci.
PCT/US2003/031717 2002-10-02 2003-10-02 Compositions therapeutiques Ceased WO2004030634A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003282722A AU2003282722A1 (en) 2002-10-02 2003-10-02 Therapeutic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41569802P 2002-10-02 2002-10-02
US60/415,698 2002-10-02

Publications (2)

Publication Number Publication Date
WO2004030634A2 WO2004030634A2 (fr) 2004-04-15
WO2004030634A3 true WO2004030634A3 (fr) 2004-09-23

Family

ID=32069900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031717 Ceased WO2004030634A2 (fr) 2002-10-02 2003-10-02 Compositions therapeutiques

Country Status (2)

Country Link
AU (1) AU2003282722A1 (fr)
WO (1) WO2004030634A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005003788A1 (de) * 2005-01-19 2006-07-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum siRNA-Moleküle zur Behandlung von Blutgefäßen
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
CA2764158A1 (fr) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides pour interference arn multivalente, compositions et procedes pour les utiliser
IL316159A (en) 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
CA2995995A1 (fr) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Nanoparticules polynucleotidiques pour la modulation de l'expression genique et leurs utilisations
JP7183167B2 (ja) 2017-02-06 2022-12-05 エムペグ エルエイ リミテッド ライアビリティ カンパニー 減少した腎クリアランスを有する多量体オリゴヌクレオチド
EP4416292A2 (fr) 2021-10-14 2024-08-21 Arsenal Biosciences, Inc. Cellules immunitaires ayant des arnsh co-exprimés et des systèmes de porte logique
CN120112638A (zh) 2022-09-13 2025-06-06 阿森纳生物科学公司 具有共表达的TGFBR shRNA的免疫细胞
JP2025532585A (ja) 2022-09-16 2025-10-01 アーセナル バイオサイエンシズ インコーポレイテッド 組み合わせ遺伝子摂動を有する免疫細胞
CN120813368A (zh) 2023-03-03 2025-10-17 阿森纳生物科学公司 靶向psma和ca9的系统
WO2025199338A1 (fr) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systèmes ciblant slc34a2 et tmprss4 et leurs procédés d'utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELBASHIR ET AL: "RNA interference is mediated by 21- and 22-nucleotide RNAs", GENES AND DEVELOPMENT, vol. 15, 2001, pages 188 - 200, XP002206453 *
FIRE ET AL: "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans", NATURE, vol. 391, 19 February 1998 (1998-02-19), pages 806 - 811, XP002977033 *
PAUL ET AL: "Effective expression of small interfering RNA in human cells", NATURE BIOTECHNOLOGY, vol. 29, May 2002 (2002-05-01), pages 505 - 508, XP001121066 *
SUI ET AL: "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells", PNAS, vol. 99, no. 8, 16 April 2002 (2002-04-16), pages 5515 - 5520, XP002964701 *
TUSCHL ET AL: "Targeted mRNA degradation by double-stranded RNA in vitro", GENES AND DEVELOPMENT, vol. 13, 1999, pages 3191 - 3197, XP002945265 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation

Also Published As

Publication number Publication date
WO2004030634A2 (fr) 2004-04-15
AU2003282722A1 (en) 2004-04-23
AU2003282722A8 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
WO2004080406A3 (fr) Compositions therapeutiques
WO2004091515A3 (fr) Conjugues arni
WO2004090108A3 (fr) Conjugues d'arni
WO2004091572A3 (fr) Compositions contenant des structures cochleaires, dirigees contre l'expression de proteines
WO2005110396A3 (fr) Lipides nitres et procedes de fabrication et d'utilisation associes
AU2003299509A1 (en) Crosslinked compounds and methods of making and using thereof
PL375691A1 (en) Imidazolopyridines and methods of making and using the same
AU2003259735A1 (en) Small-mer compositions and methods of use
AU2003285012A1 (en) Compositions comprising zopiclone derivatives and methods of making and using the same
AU2002950862A0 (en) Furanone derivatives and methods of making same
AU2003301066A1 (en) Al2o3-la2o3-y2o3-mgo ceramics, and methods of making the same
WO2004064737A3 (fr) Compositions therapeutiques
AU2003294521A1 (en) Toy construction block and method of manufacturing same
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003303926A1 (en) Ceramics and methods of making the same
WO2004030634A3 (fr) Compositions therapeutiques
TW200508233A (en) Chk-1 inhibitors
GB0303609D0 (en) Novel therapeutic method and compositions
AU2003235506A1 (en) Targeted enzymes and methods of making and using targeted enzymes.
AU2003241136A1 (en) Microlens and method of making same
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
AU2003294684A1 (en) Ketoprofen compositions and methods of making them
AU2002246950A1 (en) Hydrocapsules and method of preparation
IL163596A0 (en) Cd40 splice variants, compositions for making and methods of using thesame
GB0405940D0 (en) Lasers and methods of making them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP